| Helen Mary Burt | |
| Birth Place: | Manchester |
| Workplaces: | University of British Columbia |
| Alma Mater: | University of British Columbia University of Bath |
| Thesis Title: | Effect of crystal anisotropy and crystal defects on dissolution |
| Thesis Url: | http://www.worldcat.org/oclc/15885609 |
| Thesis Year: | 1980 |
Helen M. Burt is a British-Canadian pharmaceutical scientist who is the Angiotech Professor of Drug Delivery at the University of British Columbia. She serves as Associate Vice President of Research and Innovation at UBC. Her research considers novel therapeutics based on nanotechnology, including drug delivery systems for the treatment of bladder cancer and coronary artery disease.
Burt is from Manchester in the United Kingdom.[1] [2] During a high school trip to a local hospital, she was first introduced to pharmacy.[3] Burt was an undergraduate student at the University of Bath, where she specialised in pharmacy. She moved to Canada to complete her graduate research as a doctoral student at the University of British Columbia, where she studied anisotropy and defects on dissolution of crystals.[4]
Burt joined the faculty at the University of British Columbia in 1980.[5] Her research involves the use of nanotechnology for drug delivery. She has demonstrated that systems can provide targeted relief to different parts of the body, and release specific amounts of drug and controlled rates. In particular, Burt has studied nanocrystalline cellulose, a molecular substrate that has large surfaces areas and negative surface charges. Nanocrystalline cellulose can withstand binding of high quantities of drugs, and contain hydroxyl groups that can be used for surface modification. The hydroxyl groups can be used to selective load and release treatments, including ant-infective agents in wound dressings.[6]
Burt worked alongside Sitka Biopharma on STK-01, a polymer nanoparticle based drug-delivery system that can be used to treat bladder cancer.[7] [8] The drug, which delivers targeted chemotherapy (Docetaxel) to non-muscle invasive bladder cancer, entered clinical trials in 2017.[9] [10]
Burt co-founded the Centre for Drug Research and Development in 2004. The centre later became adMare BioInnovations, which allows biomedical scientists to translate their research into industry. In 2011, Burt was made Associate Vice President of Research and Innovation.